Treating method of nuclear factor-KB mediated diseases and dysfuction

Abstract

The present invention provides a method for treating a disease or disorder responsive to inhibition of nuclear factor-KB transcription factor, comprising administering a sulfonylaminocarbonyl derivative or a pharmaceutically acceptable salt thereof to a patient in need of treatment. The methods of the invention are useful, for example, in the treatment of rheumatoid arthritis, osteoarthritis, autoimmune diseases, psoriasis, asthma, cardiovascular disease, acute coronary syndrome, congestive heart failure, Alzheimer's disease, multiple Cirrhosis, cancer, type 2 diabetes, metabolic syndrome X, or inflammatory bowel disease.

Description

Invention field [0001] The present invention provides a method for treating diseases or disorders responsive to the inhibition of nuclear factor-κB transcription factors, which comprises administering a sulfonamidocarbonyl derivative or a pharmaceutically acceptable salt thereof to a patient in need of treatment. Background of the invention [0002] Inhibition of nuclear factor-κB ("NF-κB") transcription factor-mediated activity will provide a valuable treatment for diseases or disorders that afflict millions of people around the world. This is because NF-κB mediates the transcription of a large number of genes related to the production of proinflammatory cytokines and other biomolecules closely related to the etiology of a variety of diseases and disorders. There is no fully effective treatment for these diseases and disorders. Among these diseases and disorders considered to be responsive to the inhibition of NF-κB, it is worth noting that rheumatoid arthritis and osteoarthriti...

AI Technical Summary

Problems solved by technology

In other words, NF-κB inhibitors act upstream, inhibiting the production of multiple pro-inflammatory mediators, whereas conventional drug regimens are less effective, perhaps because they act downstream, often targeting only one of these mediators